Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Emeritus Professor Herbie Newell

Newcastle AuthorsTitleYearFull text
Christopher Matheson
Christopher Coxon
Dr Benoit Carbain
Dr Ian Hardcastle
Dr Suzannah Harnor
et al.		2-Arylamino-6-ethynylpurines are cysteine-targeting irreversible inhibitors of Nek2 kinase2020
Emeritus Professor Herbie Newell
A successful collaboration between academia, biotech and pharma led to discovery of erdafitinib, a selective FGFR inhibitor recently approved by the FDA2019
Liz Matheson
Huw Thomas
Marian Case
Dr Helen Blair
Rosanna Jackson
et al.		Glucocorticoids and selumetinib are highly synergistic in RAS pathway mutated childhood acute lymphoblastic leukemia through upregulation of BIM2019
Stephanie Myers
Duncan Miller
Dr Lauren Molyneux
Dr Mercedeh Arasta
Dr Ruth Bawn
et al.		Identification of a novel orally bioavailable ERK5 inhibitor with selectivity over p38α and BRD42019
Dr Lindi Chen
Philip Berry
Dr Jennifer Bonner
Calum Kirk
Dr Katrina Wood
et al.		Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma2019
Dr Catherine Willoughby
Huw Thomas
Dr Elaine Willmore
Suzanne Kyle
Dr Anita Wittner
et al.		Selective DNA-PKcs Inhibition Extends the Therapeutic Index of Localized Radiotherapy and Chemotherapy2019
Honorine Lebraud
Dr Richard Noble
Nicole Phillips
Dr Yan Zhao
Emeritus Professor Herbie Newell
et al.		A highly potent clickable probe for cellular imaging of MDM2 and assessing dynamic responses to MDM2-p53 inhibition2018
Christopher Coxon
Dr Suzannah Harnor
Dr Mathew Martin
Dr Benoit Carbain
Emeritus Professor Bernard Golding
et al.		Cyclin-Dependent Kinase (CDK) Inhibitors; Structure-Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines2017
Emeritus Professor Herbie Newell
Discovery & pharmacological characterization of JNJ-42756493 (Erdafitinib), a functionally selective small-molecule FGFR family inhibitor2017
Dr Lindi Chen
Philip Berry
Dr Jennifer Bonner
Dr Katrina Wood
Professor Gareth Veal
et al.		In vivo evaluation of the intravenous MDM2-p53 antagonist RO6839921 alone and in combination with temozolomide in TP53 wild-type orthotopic models of neuroblastoma2017
Carlo Bawn
Dr Martin Galler
Huw Thomas
Suzanne Kyle
Professor Nicola Curtin
et al.		PARP inhibitor rucaparib induces changes in NAD levels in cells and liver tissues as assessed by MRS2017
Dr Britta Vormoor
Yvonne Schlosser
Dr Helen Blair
Abhishek Sharma
Sarah Wilkinson
et al.		Sensitizing Ewing sarcoma to chemo- and radiotherapy by inhibition of the DNA-repair enzymes DNA protein kinase (DNA-PK) and poly-ADP-ribose polymerase (PARP) 1/22017
Dr Christopher Wong
Dr Ian Hardcastle
Christopher Matheson
Emeritus Professor Herbie Newell
Dr Mangaleswaran Sivaprakasam
et al.		Structure-guided design of purine-based probes for selective Nek2 inhibition2017
Dr Catherine Drummond
Arman Esfandiari
Dr Xiaohong Lu
Dr Claire Hutton
Dr Jennifer Jackson
et al.		TP53 mutant MDM2-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiation2016
Dr Gary Beale
Dr Emma Haagensen
Huw Thomas
Lan Wang
Charlotte Revill
et al.		Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo anti-tumour activity in colorectal cancer2016
12345678910111213141516171819